AVNS:NYE-Avanos Medical, Inc (USD)

COMMON STOCK | Medical Devices | NYE

Last Closing Price

USD 47.56

Change

0.00 (0.00)%

Market Cap

USD 2.27B

Volume

0.20M

Average Target Price

USD 45.20 (-4.96%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Avanos Medical, Inc. operates as a medical technology company that focuses on delivering medical device solutions to improve patients' quality of life in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. Its product portfolio includes digestive health products, including enteral feeding tubes and solutions; respiratory health products, such as closed airway suction systems and oral care kits; and acute pain products comprising surgical pain pumps, and cold and compression therapy systems, as well as interventional pain management solutions that include minimally invasive interventional pain therapies. The company sells its products under the MIC-KEY, CORPAK, NEOMED, BALLARD, MICROCUFF, ENDOCLEAR, ON-Q, AMBIT, GAME READY, and COOLIEF brand names. It markets its products directly to hospitals and other healthcare providers, and through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia. Address: 5405 Windward Parkway, Alpharetta, GA, United States, 30004

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-24 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ABT Abbott Laboratories

N/A

USD199.99B 59.67 27.74
MDT Medtronic plc

N/A

USD156.92B 42.55 26.50
SYK Stryker Corporation

N/A

USD90.16B 52.05 30.18
EW Edwards Lifesciences Corporati..

N/A

USD53.30B 67.60 39.85
BSX Boston Scientific Corporation

N/A

USD52.44B 14.22 69.84
ZBH Zimmer Biomet Holdings, Inc

N/A

USD33.37B 814.82 38.69
SNN Smith & Nephew plc

N/A

USD19.67B 50.84 23.64
BIO-B Bio-Rad Laboratories, Inc

N/A

USD17.72B 5.06 3.72
BIO Bio-Rad Laboratories, Inc

N/A

USD17.72B 5.10 3.72
PEN Penumbra, Inc

N/A

USD8.86B 813.79 490.23

ETFs Containing AVNS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.66% 48% F 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.66% 48% F 57% F
Trailing 12 Months  
Capital Gain 58.85% 80% B- 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 58.85% 80% B- 90% A-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -11.91% 16% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.91% 16% F 10% F
Risk Return Profile  
Volatility (Standard Deviation) 22.03% 64% D 36% F
Risk Adjusted Return -54.06% 16% F 11% F
Market Capitalization 2.27B 40% F 63% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 163.44 29% F 5% F
Price/Book Ratio 1.78 88% B+ 49% F
Price / Cash Flow Ratio -30.54 84% B 94% A
EV/EBITDA 59.48 23% F 8% F
Management Effectiveness  
Return on Equity 1.09% 54% F 37% F
Return on Invested Capital -4.83% 44% F 14% F
Return on Assets 0.44% 44% F 26% F
Debt to Equity Ratio 19.61% 70% C- 81% B-
Technical Ratios  
Short Ratio 6.83 20% F 9% F
Short Percent 4.61% 38% F 48% F
Beta 1.12 44% F 46% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector